Detecting Mild Cognitive Deficits in Parkinson's Disease: Comparison of Neuropsychological Tests

on behalf of the IPMDS Study Group “Validation of Mild Cognitive Impairment in Parkinson Disease”

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Background: Numerous neuropsychological tests and test versions are used in Parkinson's disease research, but their relative capacity to detect mild cognitive deficits and their comparability across studies are unknown. The objective of this study was to identify neuropsychological tests that consistently detect cognitive decline in PD across studies. Methods: Data from 30 normed neuropsychological tests across 20 international studies in up to 2908 nondemented PD patients were analyzed. A subset of 17 tests was administered to up to 1247 healthy controls. A 2-step meta-analytic approach using standardized scores compared performance in PD with normative data. Results: Pooled estimates of the differences between PD and site-specific healthy controls identified significant cognitive deficits in PD patients on 14 test scores across 5 commonly assessed cognitive domains (attention or working memory, executive, language, memory, and visuospatial abilities), but healthy control performance was statistically above average on 7 of these tests. Analyses based on published norms only, as opposed to direct assessment of healthy controls, showed high between-study variability that could not be accounted for and led to inconclusive results. Conclusions: Normed neuropsychological tests across multiple cognitive domains consistently detect cognitive deficits in PD when compared with site-specific healthy control performance, but relative PD performance was significantly affected by the inclusion and type of healthy controls versus the use of published norms only. Additional research is needed to identify a cognitive battery that can be administered in multisite international studies and that is sensitive to cognitive decline, responsive to therapeutic interventions, and superior to individual cognitive tests.

Original languageEnglish (US)
Pages (from-to)1750-1759
Number of pages10
JournalMovement Disorders
Volume33
Issue number11
DOIs
StatePublished - Nov 2018

Fingerprint

Neuropsychological Tests
Parkinson Disease
Aptitude
Short-Term Memory
Research
Language
Cognitive Dysfunction
Therapeutics

All Science Journal Classification (ASJC) codes

  • Neurology
  • Clinical Neurology

Cite this

on behalf of the IPMDS Study Group “Validation of Mild Cognitive Impairment in Parkinson Disease” (2018). Detecting Mild Cognitive Deficits in Parkinson's Disease: Comparison of Neuropsychological Tests. Movement Disorders, 33(11), 1750-1759. https://doi.org/10.1002/mds.110
on behalf of the IPMDS Study Group “Validation of Mild Cognitive Impairment in Parkinson Disease”. / Detecting Mild Cognitive Deficits in Parkinson's Disease : Comparison of Neuropsychological Tests. In: Movement Disorders. 2018 ; Vol. 33, No. 11. pp. 1750-1759.
@article{a0b3b10dc58f48a681299f298541b6b5,
title = "Detecting Mild Cognitive Deficits in Parkinson's Disease: Comparison of Neuropsychological Tests",
abstract = "Background: Numerous neuropsychological tests and test versions are used in Parkinson's disease research, but their relative capacity to detect mild cognitive deficits and their comparability across studies are unknown. The objective of this study was to identify neuropsychological tests that consistently detect cognitive decline in PD across studies. Methods: Data from 30 normed neuropsychological tests across 20 international studies in up to 2908 nondemented PD patients were analyzed. A subset of 17 tests was administered to up to 1247 healthy controls. A 2-step meta-analytic approach using standardized scores compared performance in PD with normative data. Results: Pooled estimates of the differences between PD and site-specific healthy controls identified significant cognitive deficits in PD patients on 14 test scores across 5 commonly assessed cognitive domains (attention or working memory, executive, language, memory, and visuospatial abilities), but healthy control performance was statistically above average on 7 of these tests. Analyses based on published norms only, as opposed to direct assessment of healthy controls, showed high between-study variability that could not be accounted for and led to inconclusive results. Conclusions: Normed neuropsychological tests across multiple cognitive domains consistently detect cognitive deficits in PD when compared with site-specific healthy control performance, but relative PD performance was significantly affected by the inclusion and type of healthy controls versus the use of published norms only. Additional research is needed to identify a cognitive battery that can be administered in multisite international studies and that is sensitive to cognitive decline, responsive to therapeutic interventions, and superior to individual cognitive tests.",
author = "{on behalf of the IPMDS Study Group “Validation of Mild Cognitive Impairment in Parkinson Disease”} and Jeroen Hoogland and {van Wanrooij}, {Lennard L.} and Boel, {Judith A.} and Goldman, {Jennifer G.} and Stebbins, {Glenn T.} and Dalrymple-Alford, {John C.} and Connie Marras and Adler, {Charles H.} and Carme Junque and Pedersen, {Kenn F.} and Brit Mollenhauer and Zabetian, {Cyrus P.} and Eslinger, {Paul J.} and Lewis, {Simon J.G.} and Wu, {Ruey Meei} and Martin Klein and Rodriguez-Oroz, {Maria C.} and Cammisuli, {Davide M.} and Paolo Barone and Roberta Biundo and {de Bie}, {Rob M.A.} and Schmand, {Ben A.} and Tr{\"o}ster, {Alexander I.} and Burn, {David J.} and Irene Litvan and Filoteo, {J. Vincent} and Geurtsen, {Gert J.} and Daniel Weintraub",
year = "2018",
month = "11",
doi = "10.1002/mds.110",
language = "English (US)",
volume = "33",
pages = "1750--1759",
journal = "Movement Disorders",
issn = "0885-3185",
publisher = "John Wiley and Sons Inc.",
number = "11",

}

on behalf of the IPMDS Study Group “Validation of Mild Cognitive Impairment in Parkinson Disease” 2018, 'Detecting Mild Cognitive Deficits in Parkinson's Disease: Comparison of Neuropsychological Tests', Movement Disorders, vol. 33, no. 11, pp. 1750-1759. https://doi.org/10.1002/mds.110

Detecting Mild Cognitive Deficits in Parkinson's Disease : Comparison of Neuropsychological Tests. / on behalf of the IPMDS Study Group “Validation of Mild Cognitive Impairment in Parkinson Disease”.

In: Movement Disorders, Vol. 33, No. 11, 11.2018, p. 1750-1759.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Detecting Mild Cognitive Deficits in Parkinson's Disease

T2 - Comparison of Neuropsychological Tests

AU - on behalf of the IPMDS Study Group “Validation of Mild Cognitive Impairment in Parkinson Disease”

AU - Hoogland, Jeroen

AU - van Wanrooij, Lennard L.

AU - Boel, Judith A.

AU - Goldman, Jennifer G.

AU - Stebbins, Glenn T.

AU - Dalrymple-Alford, John C.

AU - Marras, Connie

AU - Adler, Charles H.

AU - Junque, Carme

AU - Pedersen, Kenn F.

AU - Mollenhauer, Brit

AU - Zabetian, Cyrus P.

AU - Eslinger, Paul J.

AU - Lewis, Simon J.G.

AU - Wu, Ruey Meei

AU - Klein, Martin

AU - Rodriguez-Oroz, Maria C.

AU - Cammisuli, Davide M.

AU - Barone, Paolo

AU - Biundo, Roberta

AU - de Bie, Rob M.A.

AU - Schmand, Ben A.

AU - Tröster, Alexander I.

AU - Burn, David J.

AU - Litvan, Irene

AU - Filoteo, J. Vincent

AU - Geurtsen, Gert J.

AU - Weintraub, Daniel

PY - 2018/11

Y1 - 2018/11

N2 - Background: Numerous neuropsychological tests and test versions are used in Parkinson's disease research, but their relative capacity to detect mild cognitive deficits and their comparability across studies are unknown. The objective of this study was to identify neuropsychological tests that consistently detect cognitive decline in PD across studies. Methods: Data from 30 normed neuropsychological tests across 20 international studies in up to 2908 nondemented PD patients were analyzed. A subset of 17 tests was administered to up to 1247 healthy controls. A 2-step meta-analytic approach using standardized scores compared performance in PD with normative data. Results: Pooled estimates of the differences between PD and site-specific healthy controls identified significant cognitive deficits in PD patients on 14 test scores across 5 commonly assessed cognitive domains (attention or working memory, executive, language, memory, and visuospatial abilities), but healthy control performance was statistically above average on 7 of these tests. Analyses based on published norms only, as opposed to direct assessment of healthy controls, showed high between-study variability that could not be accounted for and led to inconclusive results. Conclusions: Normed neuropsychological tests across multiple cognitive domains consistently detect cognitive deficits in PD when compared with site-specific healthy control performance, but relative PD performance was significantly affected by the inclusion and type of healthy controls versus the use of published norms only. Additional research is needed to identify a cognitive battery that can be administered in multisite international studies and that is sensitive to cognitive decline, responsive to therapeutic interventions, and superior to individual cognitive tests.

AB - Background: Numerous neuropsychological tests and test versions are used in Parkinson's disease research, but their relative capacity to detect mild cognitive deficits and their comparability across studies are unknown. The objective of this study was to identify neuropsychological tests that consistently detect cognitive decline in PD across studies. Methods: Data from 30 normed neuropsychological tests across 20 international studies in up to 2908 nondemented PD patients were analyzed. A subset of 17 tests was administered to up to 1247 healthy controls. A 2-step meta-analytic approach using standardized scores compared performance in PD with normative data. Results: Pooled estimates of the differences between PD and site-specific healthy controls identified significant cognitive deficits in PD patients on 14 test scores across 5 commonly assessed cognitive domains (attention or working memory, executive, language, memory, and visuospatial abilities), but healthy control performance was statistically above average on 7 of these tests. Analyses based on published norms only, as opposed to direct assessment of healthy controls, showed high between-study variability that could not be accounted for and led to inconclusive results. Conclusions: Normed neuropsychological tests across multiple cognitive domains consistently detect cognitive deficits in PD when compared with site-specific healthy control performance, but relative PD performance was significantly affected by the inclusion and type of healthy controls versus the use of published norms only. Additional research is needed to identify a cognitive battery that can be administered in multisite international studies and that is sensitive to cognitive decline, responsive to therapeutic interventions, and superior to individual cognitive tests.

UR - http://www.scopus.com/inward/record.url?scp=85053441587&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85053441587&partnerID=8YFLogxK

U2 - 10.1002/mds.110

DO - 10.1002/mds.110

M3 - Article

C2 - 30216541

AN - SCOPUS:85053441587

VL - 33

SP - 1750

EP - 1759

JO - Movement Disorders

JF - Movement Disorders

SN - 0885-3185

IS - 11

ER -

on behalf of the IPMDS Study Group “Validation of Mild Cognitive Impairment in Parkinson Disease”. Detecting Mild Cognitive Deficits in Parkinson's Disease: Comparison of Neuropsychological Tests. Movement Disorders. 2018 Nov;33(11):1750-1759. https://doi.org/10.1002/mds.110